Showing results (41-50 of 102) with videos related to

Sort By:
Pageof 11
Clinical Pharmacology and Therapeutics|August 13, 2015
Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratioF Thomas, I Hennebelle, C Delmas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2016
How to report toxicity associated with targeted therapies?B Cabarrou, J M Boher, E Bogart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 2, 2013
Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma GroupS Cousin, J Y Blay, F Bertucci, et al.
British Journal of Cancer|April 21, 2011
Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) studyN Penel, M V Glabbeke, S Mathoulin-Pelissier, et al.
ESMO Open|April 13, 2023
Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumorsA Dufresne, D Pissaloux, C Ngo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2013
GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative StudyA Italiano, A Le Cesne, C Bellera, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|July 29, 2019
Adjuvant management of operated uterine sarcomas: A single institution experienceA Cordoba, J Prades, L Basson, et al.
ESMO Open|May 24, 2025
COREGO: drug-drug interaction analysis on the efficacy and safety of regorafenib in patients with a sarcoma: pooled analysis of the data from the REGOSARC and REGOBONE trialsF Rethouze, S Risbourg, C Schiffler, et al.
British Journal of Cancer|October 24, 2013
A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumoursA Adenis, I Ray-Coquard, A Italiano, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 28, 2016
Complication-related removal of totally implantable venous access port systems: Does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year prospective study of 4045 patientsA Kakkos, L Bresson, D Hudry, et al.
Pageof 11